Your browser doesn't support javascript.
loading
One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting ß2-agonist in UK primary care settings.
Buhl, Roland; Heaney, Liam G; Loefroth, Emil; Larbig, Michael; Kostikas, Konstantinos; Conti, Valentino; Cao, Hui.
Afiliación
  • Buhl R; Pulmonary Department, Mainz University Hospital, Mainz, Germany. Electronic address: Roland.Buhl@unimedizin-mainz.de.
  • Heaney LG; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.
  • Loefroth E; Novartis Sverige AB, Kista, Sweden.
  • Larbig M; Novartis Pharma AG, Basel, Switzerland.
  • Kostikas K; Respiratory Medicine Department, University of Ioannina Medical School, Ioannina, Greece.
  • Conti V; Novartis Ireland Limited, Dublin, Ireland.
  • Cao H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Respir Med ; 162: 105859, 2020 02.
Article en En | MEDLINE | ID: mdl-31916534
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Peloideterapia Asunto principal: Asma / Corticoesteroides Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Respir Med Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Peloideterapia Asunto principal: Asma / Corticoesteroides Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Respir Med Año: 2020 Tipo del documento: Article